Correction: Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-a and -d, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (Gastroenterology (2016) 150(5) (1147–1159.e5) (S0016508516001402) (10.1053/j.gastro.2016.01.038));Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Gastroenterology

Volumn 150, Issue 5, 2016, Pages 1147-1159.e5

  Ratziu, Vlad ^a,b   Harrison, Stephen A ^c   Francque, Sven ^d   Bedossa, Pierre ^e   Lehert, Philippe ^f,g   Serfaty, Lawrence ^h   Romero Gomez, Manuel ⁱ   Boursier, Jérôme ^j   Abdelmalek, Manal ^k   Caldwell, Steve ^l   Drenth, Joost ^m   Anstee, Quentin M ⁿ   Hum, Dean ^o   Hanf, Remy ^o   Roudot, Alice ^o   Megnien, Sophie ^o   Staels, Bart ^p   Sanyal, Arun ^q   Mathurin, P ^r   Gournay, J ^r   Nguyen Khac, E ^r   De Ledinghen, V ^r   Larrey, D ^r   Tran, A ^r   Bourliere, M ^r   Maynard Muet, M ^r   Asselah, T ^r   Henrion, J ^r   Nevens, F ^r   Cassiman, D ^r   Geerts, A ^r   Moreno, C ^r   Beuers, U H ^r   Galle, P R ^r   Spengler, U ^r   Bugianesi, E ^r   Craxi, A ^r   Angelico, M ^r   Fargion, S ^r   Voiculescu, M ^r   Gheorghe, L ^r   Preotescu, L ^r   Caballeria, J ^r   Andrade, R J ^r   Crespo, J ^r   Callera, J L ^r   Ala, A ^r   Aithal, G ^r   Abouda, G ^r   Luketic, V ^r   Huang, M A ^r   Gordon, S ^r   Pockros, P ^r   Poordad, F ^r   Shores, N ^r   Moehlen, M W ^r   Bambha, K ^r   Clark, V ^r   Satapathy, S ^r   Parekh, S ^r   Reddy, R K ^r   Sheikh, M Y ^r   Szabo, G ^r   Vierling, J ^r   Foster, T ^r   Umpierrez, G ^r   Chang, C ^r   Box, T ^r   Gallegos Orozco, J ^r   more..

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e BEAUJON HOSPITAL   (France)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^j ANGERS UNIVERSITY HOSPITAL   (France)

^k DUKE UNIVERSITY   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ NEWCASTLE UNIVERSITY   (United Kingdom)

^o Genfit SA   (France)

^p UNIV LILLE   (France)

^q VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^r NONE

more..

Author keywords

fatty liver; NAFLD; PPARA; PPARD

Indexed keywords

ELAFIBRANOR; GLUCOSE; LIPID; LIVER ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PLACEBO; 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPENYL)PHENOXYL)-2-METHYLPROPANOIC ACID; BIOLOGICAL MARKER; CHALCONE DERIVATIVE; GASTROINTESTINAL AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROPIONIC ACID DERIVATIVE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; ASTHENIA; ATAXIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FASCICULATION; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER BIOPSY; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PARKINSON DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SPONTANEOUS ABORTION; TREATMENT OUTCOME; TREMOR; UNITED STATES; VOMITING; AGONISTS; BIOPSY; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PATHOLOGY; PHASE 2 CLINICAL TRIAL; REMISSION; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; STATISTICAL MODEL; TIME FACTOR;

ADULT; BIOMARKERS; BIOPSY; CHALCONES; DOUBLE-BLIND METHOD; EUROPE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTENTION TO TREAT ANALYSIS; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PPAR ALPHA; PPAR GAMMA; PROPIONATES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84960140218     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.05.017     Document Type: Erratum

References (36)

1. N. Chalasani, Z. Younossi, J.E. Lavine, and et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
2. V. Ratziu, S. Bellentani, H. Cortez-Pinto, and et al. A position paper on NAFLD/NASH based on the EASL 2009 Special Conference J Hepatol 53 2010 372 384
3. G. Vernon, A. Baranova, and Z.M. Younossi Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 34 2011 274 285
4. M.R. Charlton, J.M. Burns, R.A. Pedersen, and et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 141 2011 1249 1253
5. M. Ekstedt, L.E. Franzen, U.L. Mathiesen, and et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 2006 865 873
6. H. Yki-Jarvinen Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome Lancet Diabetes Endocrinol 2 2014 901 910
7. P. Angulo, D.E. Kleiner, S. Dam-Larsen, and et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease Gastroenterology 149 2015 389 397
8. M. Ekstedt, H. Hagstrom, P. Nasr, and et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology 61 2015 1547 1554
9. R. Belfort, S.A. Harrison, K. Brown, and et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2006 2297 2307
10. G.P. Aithal, J.A. Thomas, P.V. Kaye, and et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis Gastroenterology 135 2008 1176 1184
11. A.J. Sanyal, N. Chalasani, K.V. Kowdley, and et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
12. M. Pawlak, P. Lefebvre, and B. Staels Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease J Hepatol 62 2015 720 733
13. L.A. Bojic, and M.W. Huff Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player Curr Opin Lipidol 24 2013 171 177
14. J.I. Odegaard, R.R. Ricardo-Gonzalez, A. Red Eagle, and et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance Cell Metab 7 2008 496 507
15. U. Riserus, D. Sprecher, T. Johnson, and et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men Diabetes 57 2008 332 339
16. B. Staels, A. Rubenstrunk, B. Noel, and et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis Hepatology 58 2013 1941 1952
17. B. Cariou, R. Hanf, S. Lambert-Porcheron, and et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects Diabetes Care 36 2013 2923 2930
18. B. Cariou, Y. Zair, B. Staels, and et al. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism Diabetes Care 34 2011 2008 2014
19. D.E. Kleiner, and P. Bedossa Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists Gastroenterology 149 2015 1305 1308
20. M.J. Armstrong, P. Gaunt, G.P. Aithal, and et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Lancet 387 10019 2016 679 690
21. B.A. Neuschwander-Tetri, R. Loomba, A.J. Sanyal, and et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 385 9972 2015 956 965
22. A.C. Tamhane, Y. Hochberg, and C.W. Dunnett Multiple test procedures for dose finding Biometrics 52 1996 21 37
23. Z.M. Younossi, M. Stepanova, N. Rafiq, and et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality Hepatology 53 2011 1874 1882
24. V. Ratziu, S. Caldwell, and B.A. Neuschwander-Tetri Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues Hepatology 52 2010 2206 2215
25. A.J. Sanyal, E.M. Brunt, D.E. Kleiner, and et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis Hepatology 54 2011 344 353
26. A.J. Sanyal, S.L. Friedman, A.J. McCullough, and et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop Hepatology 61 2015 1392 1405
27. J.E. Everhart, E.C. Wright, Z.D. Goodman, and et al. Prognostic value of Ishak fibrosis stage: findings from the HALT-C trial Hepatology 51 2009 585 594
28. J. Parkes, P. Roderick, S. Harris, and et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease Gut 59 2010 1245 1251
29. F. Imazeki Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study Hepatology 38 2003 493 502
30. M. Ekstedt, L.E. Franzen, U.L. Mathiesen, and et al. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression Scand J Gastroenterol 47 2012 108 115
31. S. Francque, A. Verrijken, S. Caron, and et al. PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis J Hepatol 63 2015 164 173
32. J.E. Lavine, J.B. Schwimmer, M.L. Van Natta, and et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial JAMA 305 2011 1659 1668
33. R.D. Ting, A.C. Keech, P.L. Drury, and et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study Diabetes Care 35 2012 218 225
34. D.E. Bonds, T.E. Craven, J. Buse, and et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience Diabetologia 55 2012 1641 1650
35. T.M. Davis, R. Ting, J.D. Best, and et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2011 280 290
36. M. Jun, C. Foote, J. Lv, and et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 9729 2010 1875 1884